Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Infliximab and biosimilar Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Infliximab and biosimilar Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Infliximab
      • 1.3.3 infliximab-dyyb
      • 1.3.4 infliximab-abda
    • 1.4 Market Segment by Application
      • 1.4.1 Global Infliximab and biosimilar Market Share by Application (2019-2025)
      • 1.4.2 Crohn's Disease
      • 1.4.3 Pediatric Crohn's Disease
      • 1.4.4 Ulcerative Colitis
      • 1.4.5 Rheumatoid Arthritis
      • 1.4.6 Ankylosing Spondylitis
      • 1.4.7 Psoriatic Arthritis
      • 1.4.8 Plaque Psoriasis
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Infliximab and biosimilar Market Size
      • 2.1.1 Global Infliximab and biosimilar Revenue 2014-2025
      • 2.1.2 Global Infliximab and biosimilar Sales 2014-2025
    • 2.2 Infliximab and biosimilar Growth Rate by Regions
      • 2.2.1 Global Infliximab and biosimilar Sales by Regions 2014-2019
      • 2.2.2 Global Infliximab and biosimilar Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Infliximab and biosimilar Sales by Manufacturers
      • 3.1.1 Infliximab and biosimilar Sales by Manufacturers 2014-2019
      • 3.1.2 Infliximab and biosimilar Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Infliximab and biosimilar Revenue by Manufacturers (2014-2019)
      • 3.2.2 Infliximab and biosimilar Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Infliximab and biosimilar Market Concentration Ratio (CR5 and HHI)
    • 3.3 Infliximab and biosimilar Price by Manufacturers
    • 3.4 Key Manufacturers Infliximab and biosimilar Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Infliximab and biosimilar Market
    • 3.6 Key Manufacturers Infliximab and biosimilar Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Infliximab Sales and Revenue (2014-2019)
      • 4.1.2 infliximab-dyyb Sales and Revenue (2014-2019)
      • 4.1.3 infliximab-abda Sales and Revenue (2014-2019)
    • 4.2 Global Infliximab and biosimilar Sales Market Share by Type
    • 4.3 Global Infliximab and biosimilar Revenue Market Share by Type
    • 4.4 Infliximab and biosimilar Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Infliximab and biosimilar Sales by Application

    6 United States

    • 6.1 United States Infliximab and biosimilar Breakdown Data by Company
    • 6.2 United States Infliximab and biosimilar Breakdown Data by Type
    • 6.3 United States Infliximab and biosimilar Breakdown Data by Application

    7 European Union

    • 7.1 European Union Infliximab and biosimilar Breakdown Data by Company
    • 7.2 European Union Infliximab and biosimilar Breakdown Data by Type
    • 7.3 European Union Infliximab and biosimilar Breakdown Data by Application

    8 China

    • 8.1 China Infliximab and biosimilar Breakdown Data by Company
    • 8.2 China Infliximab and biosimilar Breakdown Data by Type
    • 8.3 China Infliximab and biosimilar Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Infliximab and biosimilar Breakdown Data by Company
    • 9.2 Rest of World Infliximab and biosimilar Breakdown Data by Type
    • 9.3 Rest of World Infliximab and biosimilar Breakdown Data by Application
    • 9.4 Rest of World Infliximab and biosimilar Breakdown Data by Countries
      • 9.4.1 Rest of World Infliximab and biosimilar Sales by Countries
      • 9.4.2 Rest of World Infliximab and biosimilar Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Janssen Biotech
      • 10.1.1 Janssen Biotech Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Infliximab and biosimilar
      • 10.1.4 Infliximab and biosimilar Product Introduction
      • 10.1.5 Janssen Biotech Recent Development
    • 10.2 Merck and Co.
      • 10.2.1 Merck and Co. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Infliximab and biosimilar
      • 10.2.4 Infliximab and biosimilar Product Introduction
      • 10.2.5 Merck and Co. Recent Development
    • 10.3 Pfizer
      • 10.3.1 Pfizer Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Infliximab and biosimilar
      • 10.3.4 Infliximab and biosimilar Product Introduction
      • 10.3.5 Pfizer Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Infliximab and biosimilar Sales Channels
      • 11.2.2 Infliximab and biosimilar Distributors
    • 11.3 Infliximab and biosimilar Customers

    12 Market Forecast

    • 12.1 Global Infliximab and biosimilar Sales and Revenue Forecast 2019-2025
    • 12.2 Global Infliximab and biosimilar Sales Forecast by Type
    • 12.3 Global Infliximab and biosimilar Sales Forecast by Application
    • 12.4 Infliximab and biosimilar Forecast by Regions
      • 12.4.1 Global Infliximab and biosimilar Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Infliximab and biosimilar Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
      In 2019, the market size of Infliximab and biosimilar is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Infliximab and biosimilar.

      This report studies the global market size of Infliximab and biosimilar, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Infliximab and biosimilar sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Janssen Biotech
      Merck and Co.
      Pfizer
      ...

      Market Segment by Product Type
      Infliximab
      infliximab-dyyb
      infliximab-abda

      Market Segment by Application
      Crohn's Disease
      Pediatric Crohn's Disease
      Ulcerative Colitis
      Rheumatoid Arthritis
      Ankylosing Spondylitis
      Psoriatic Arthritis
      Plaque Psoriasis

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Infliximab and biosimilar status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Infliximab and biosimilar manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Infliximab and biosimilar are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now